OLD AND NEW IN LIPID LOWERING THERAPY:
FOCUS ON THE EMERGING DRUGS
DANIELA BARTOȘ, CAMELIA DIACONU, ELISABETA BĂDILĂ*,
ANA MARIA DARABAN
University of Medicine and Pharmacy Carol Davila,
Internal Medicine Clinic, Clinical Emergency Hospital of Bucharest,
România
* corresponding author: elisabeta.badila@gmail.com
DownloadDownload Full Article

Abstract:

The link between cholesterol and atherosclerosis has been long known. Studies
on HDL (high density lipoprotein) cholesterol showed that it has two important roles: one
in the transport of cholesterol and another directly on vascular endothelium, with a
protective action and potential anti-atherogenic effects. Statins are the most common lipidlowering
drugs. Other drugs used in the treatment dyslipidemia are bile acid sequestrants,
nicotinic acid, ezetimibe, probucol, neomycin, and fibrates. Because the response to
treatment is not always satisfactory, new classes of drugs with different mechanisms of
action have been developed in the latest years.






Top